Abstract
Ferroptosis plays a dual role in cancer, which is known to be affected to antitumor immune responses. However, the association between ferroptosis and antitumor immune responses is uncertain in lung adenocarcinoma (LUAD). In this work, 38 ferroptosis-related genes (FRGs) and 429 immune-related genes (IRGs) were identified as being differentially expressed between tumor and normal samples. Two risk score formulas consisting of seven FRGs and four IRGs, respectively, were developed by Lasso-penalized Cox regression and verified in the GSE13213 dataset. The CIBERSORT algorithm was used to estimate the relative abundance of immune cells in tumors. The correlation between FRGs and immune cells was evaluated using the TIMER database. The results indicated that the development of ferroptosis was synergistic with that of anti-tumor immunity in LUAD. The concordance index and calibration curves showed that the performance of a nomogram that combines clinical staging and risk scores is superior to that of models using a single prognostic factor. In conclusion, ferroptosis might be synergistic with anti-tumor immunity in LUAD. The combined nomogram could reliably predict the probability of overall survival of LUAD patients. These findings may be useful for future investigation of prognostic value and therapeutic potential related to ferroptosis and tumor immunity in LUAD.
Highlights
Lung cancer is the most common type of cancer and the leading cause of cancer-related death worldwide
By univariate Cox regression analysis, 16 ferroptosis-related genes (FRGs) and 51 immune-related genes (IRGs) were identified as being related to prognosis (Figures 2C,D; Supplementary Tables S6, S7)
The incidence of lung adenocarcinoma (LUAD) has significantly increased compared with lung squamous cell carcinoma (LUSC) (Kinoshita et al, 2016)
Summary
Lung cancer is the most common type of cancer and the leading cause of cancer-related death worldwide. An estimated 1.8 million deaths from lung cancer occurred in 2020 (Sung et al, 2021). Lung adenocarcinoma (LUAD) is the most prevalent subtype of lung cancer, accounting for about 40% (Ma et al, 2013). There are many therapeutic options for LUAD, overall prognosis remains poor (Herbst et al, 2018). It is necessary to further explore factors related to survival time that may contribute to the development of more effective treatment methods for lung adenocarcinoma
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
